Results 221 to 230 of about 102,788 (290)
We report the UK experience of autologous haematopoietic stem cell transplantation (AHSCT) for multiple sclerosis (MS) in 364 patients. In our observational study, transplant‐related mortality was 1.4%, Epstein–Barr virus reactivation occurred in 75.9%, while disability progression‐free survival was 83.5% at 2 years post‐AHSCT and 62.4% at 5 years.
Majid Kazmi+18 more
wiley +1 more source
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu+17 more
wiley +1 more source
Autoimmune enteropathy associated with T cell large granular lymphocytic leukemia in a patient with <i>BACH2</i> mutation: a case report. [PDF]
Arshi J, Evans AG, Liesveld J, Hao Y.
europepmc +1 more source
Summary Human leukocyte antigen (HLA)‐haploidentical haematopoietic cell transplantation (haplo‐HCT) is a suitable salvage strategy in children with haematological malignancies experiencing either relapse or graft failure (GF) after the first HCT.
Riccardo Masetti+20 more
wiley +1 more source
Chromatin remodeling in lymphocytic function and fate: the multifaceted roles of SWI/SNF complex. [PDF]
Miao R, Liu Y, Shen S, Wang W, Wang S.
europepmc +1 more source
Leukemia cutis (chronic lymphocytic leukemia-low grade B cell)
openaire +5 more sources
CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin+2 more
wiley +1 more source
In oncological patients SIR measures like the mGPS have great impact on prognosis at starting therapy. We recorded at admission for allo‐HCT the mGPS in 2201 patients: score 0 CRP/sALB normal; score 1 CRP >10mg/dl; score 2 CRP >10mg/dl + sALB <35g/L. Multivariate analysis revealed a significant impact with a low GPS score for OS: mGPS 1 vs.
Hartmut Bertz+11 more
wiley +1 more source